LOS
ANGELES, March 5, 2024 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company
focused on developing and commercializing precision therapies for
patients with mTOR-driven cancers, today announced poster
presentations at the 2024 American Association for Cancer Research
(AACR), taking place April 5-10, 2024, in San Diego,
CA.
AACR poster presentation details are below:
Title: "Evaluation of nab-sirolimus in
combination with fulvestrant or PI3K pathway inhibitors to overcome
resistance in breast cancer cell lines"
Session
Title: Reversal of Drug Resistance 2
Location: Poster Section 25, Board Number 6
Abstract Number: 7196
Date/Time: Wednesday Apr 10,
2024, 9:00 AM - 12:30 PM
Presenting Author: Shihe Hou, PhD
Title: "Correlation of nab-sirolimus tumor drug
levels and improved tumor suppression in KRAS G12C non-small cell
lung cancer xenografts treated with nab-sirolimus in combination
with KRAS inhibitors"
Session Title: Targeting Kinase
and ERK Pathways
Location: Poster Section 46, Board Number 3
Abstract Number: 6486
Date/Time: Tuesday Apr 9, 2024
1:30 PM - 5:00 PM
Presenting Author: Shihe Hou, PhD
More information can be found on the AACR meeting
website.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for cancers to bring transformational therapies
to cancer patients with alterations in the mTOR pathway, a key
regulator of cell growth and cancer progression. Aadi received FDA
approval and has commercialized FYARRO® for the
treatment of adult patients with locally advanced unresectable or
metastatic malignant perivascular epithelioid cell tumor
(PEComa).
Aadi has also initiated clinical trials of nab-sirolimus
as a single agent or in combination for the treatment of other
mTOR-driven cancers. PRECISION 1 (NCT05103358), a Phase 2
tumor-agnostic registration-intended trial in mTOR inhibitor-naïve
malignant solid tumors
harboring TSC1 or TSC2 inactivating
alterations is currently enrolling in the US and globally. A
multicenter, open-label, single-arm Phase 2 study of
nab-sirolimus in combination with letrozole is currently
enrolling patients with advanced or recurrent endometrioid
endometrial cancer (NCT05997017); nab-sirolimus is also
being investigated as a single agent in an open-label, single-arm,
Phase 2 trial for the treatment of patients with neuroendocrine
tumors of the GI tract, pancreas, or lung (NCT05997056). More
information on the Company's development pipeline is available on
the Aadi website at www.aadibio.com and connect with us
on X (formerly Twitter) and LinkedIn.
Contact:
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-multiple-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2024-302080277.html
SOURCE Aadi Bioscience